The role of kidney transplantation and phosphate binder use in vitamin K status

PLoS One. 2018 Aug 30;13(8):e0203157. doi: 10.1371/journal.pone.0203157. eCollection 2018.

Abstract

Background: Cardiovascular disease is the leading cause of death in end-stage renal disease and is strongly associated with vascular calcification. Both kidney transplantation and phosphate binders may lower the risk of vascular calcification. Vascular calcification is actively inhibited by vitamin-K-dependent matrix γ-carboxyglutamic acid protein (MGP). Whether kidney transplantation or phosphate binders affect vitamin K status is unknown. Therefore, we studied the influence of kidney transplantation and phosphate binder use on vitamin K status.

Methods: We measured plasma desphospho-uncarboxylated MGP (dp-ucMGP), a marker reflecting low vitamin K status, in a cross-sectional study of patients on hemodialysis (n = 82), peritoneal dialysis (n = 31) or who recently received a kidney transplantation (n = 36). By medication inventory, we assessed phosphate binder use. With linear regression, we assessed the influence of kidney transplantation and phosphate binder use on natural-log-transformed dp-ucMGP, adjusting for potential confounders.

Results: Mean age of patients was 52±13 years; 102 (68%) were male. Dp-ucMGP levels were significantly lower in kidney transplant recipients (median 689 pmol/L) compared to patients on dialysis (median 1537 pmol/L, p<0.001). Eighty-nine patients on dialysis used phosphate binders. Using any phosphate binder was not associated with dp-ucMGP levels (median 1637 pmol/L, p = 0.09) compared to no phosphate binders (median 1142 pmol/L). Twenty-six patients used sevelamer monotherapy, which was associated with higher dp-ucMGP levels (median 1740 pmol/L, p = 0.04) after adjusting for age, sex and vitamin K antagonist use.

Conclusions: Recent kidney transplantation is associated with lower dp-ucMGP levels suggesting improved vitamin K status after transplantation. Sevelamer monotherapy is associated with higher dp-ucMGP levels suggesting worsening of vitamin K status. Both findings warrant more attention to vitamin K status in patients on dialysis, as vitamin K is necessary for protection against vascular calcification.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcium-Binding Proteins / blood*
  • Chelating Agents / adverse effects*
  • Chelating Agents / therapeutic use
  • Cross-Sectional Studies
  • Extracellular Matrix Proteins / blood*
  • Female
  • Humans
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / therapy
  • Kidney Transplantation*
  • Male
  • Matrix Gla Protein
  • Middle Aged
  • Prospective Studies
  • Renal Dialysis
  • Sevelamer / adverse effects
  • Sevelamer / therapeutic use
  • Vitamin K / antagonists & inhibitors

Substances

  • Calcium-Binding Proteins
  • Chelating Agents
  • Extracellular Matrix Proteins
  • Vitamin K
  • Sevelamer

Grants and funding

This work was supported by unrestricted grants from Amgen, Baxter, Fresenius Medical Care, Novartis, Roche and Shire Pharmaceuticals. T.T. Jansz was supported financially by a grant from the Wellerdieck de Goede Foundation with mediation from Friends of UMC Utrecht. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.